(62) reported an impressive response to combination therapy with BRAF and MEK inhibitor in a case of BRAF V600E-mutant epithelioid GBM (eGBM) with diffuse metastatic dissemination in the spine, a condition usually associated with a poor prognosis, with a median survival of 3 months. The gene discussed is BRAF; the disease is glioblastoma.